Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Australian Clinical LabsASX:ACL -0.83%56 FCF Margin % is 16.26% as of Dec. 2025, which is 28% below its 10-year median of 22.51. GuruFocus rates ASX:ACL with a GF Score™ of 56/100 and a GF Value™ of A$3.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Australian Clinical Labs ranks better than 90.64% on this metric.
The historical rank and industry rank for Australian Clinical Labs's FCF Margin % or its related term are showing as below:
ASX:ACL'
s FCF Margin % Range Over the Past 10 Years
Min: 19.76 Med: 22.51 Max: 26.57
Current: 21.43
During the past 6 years, the highest FCF Margin % of Australian Clinical Labs was 26.57%. The lowest was 19.76%. And the median was 22.51%.
ASX:ACL's FCF Margin % is ranked better than 90.64% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.96
vs ASX:ACL: 21.43
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ACL vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Australian Clinical Labs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Australian Clinical Labs (ASX:ACL) has a FCF Margin % of 16.26% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Australian Clinical Labs and its competitors. This is 28% below median its historical median of 22.51. Over the past decade, Australian Clinical Labs' FCF Margin % has ranged from 19.76 to 26.57. According to the industry distribution chart, Australian Clinical Labs ranks #19 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 9.4%.
Is Australian Clinical Labs' FCF Margin % too high?
Australian Clinical Labs' current FCF Margin % of 16.26% is 28% below median its 10-year median of 22.51. Over the past 10 years, this metric has ranged from a low of 19.76 to a high of 26.57. Based on the distribution chart, Australian Clinical Labs ranks #19 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Australian Clinical Labs has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #19 out of 203 companies for FCF Margin %. This places Australian Clinical Labs in the top 9% of its industry — outperforming the majority of peers. Historically, Australian Clinical Labs' own FCF Margin % has ranged from 19.76 to 26.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Australian Clinical Labs and its competitors. Australian Clinical Labs's current FCF Margin % is 16.26%, which is 28% below median its own 10-year median of 22.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Modestly Undervalued. The stock's GF Value™ is A$3.06, compared to a current price of A$2.38 — trading 22.2% below its estimated fair value. The current FCF Margin % is 16.26%, which is 28% below median its 10-year median of 22.51. Australian Clinical Labs' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current FCF Margin % is 16.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.38 is trading 22.2% below its estimated GF Value™ of A$3.06.
GuruFocus considers Australian Clinical Labs to be Modestly Undervalued.
Key valuation signals for ASX:ACL:
FCF Margin %: 16.26% (28% below median its 10-year median of 22.51)
GF Value™: A$3.06 vs. price of A$2.38 (22.2% below fair value)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
56GF Score
Get the complete analysis for ASX:ACL
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
